Combination Therapy in Psoriatic Arthritis

Saakshi Khattri, MB BS, MD


May 27, 2020

In patients with psoriatic arthritis (PsA), methotrexate is the most commonly used first-line conventional synthetic disease-modifying antirheumatic drug (csDMARD), and it is included in all major treatment guidelines.

Despite wide use in clinical practice, methotrexate is not approved for the treatment of PsA in the United States and many other countries. Furthermore, data on the effectiveness of combining csDMARDs (including methotrexate) with anti-TNF agents remain conflicting.

Dr Saakshi Khattri of Mount Sinai discusses the role of such combination therapy in the treatment of patients with PsA.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.